Osteotech/Medtronic
On August 17, 2010, Osteotech (Nasdaq: OSTE) announced an agreement to be acquired by Medtronic Inc., (NYSE: MDT) for $6.50 per share in cash, or approximately $123 million.
Osteotech is a leader in the growing field of biologic products for regenerative healing, and has pioneered several innovative technology platforms including Grafton demineralized bone matrix, a family of products which has a large and growing body of evidence supporting its best-in-class bone generating capabilities.